Core Insights - Zhejiang Jingxin Pharmaceutical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1] - The company focuses on innovation-driven pharmaceutical development, targeting two core disease areas: central nervous system diseases and cardiovascular and cerebrovascular diseases [1] - Jingxin Pharmaceutical's business model combines the commercialization of existing products with the ongoing development of its product pipeline [1] Company Overview - Jingxin Pharmaceutical (002020.SZ) offers a diverse product portfolio that includes drugs (both generic and innovative), traditional Chinese medicine, biological agents, active pharmaceutical ingredients, and medical devices [1]

Group 1 - The core viewpoint of the article is that Zhejiang Jingxin Pharmaceutical Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [1] - Jingxin Pharmaceutical is characterized as an innovation-driven pharmaceutical group focusing on two main disease areas: central nervous system diseases and cardiovascular and cerebrovascular diseases [1] - The company's business model combines the commercialization of already listed products with the continuous advancement of its product pipeline [1] Group 2 - The current product portfolio includes drugs (such as generic drugs, innovative drugs, traditional Chinese medicine, and biological agents), active pharmaceutical ingredients, and medical devices [1]

据港交所文件：浙江京新药业股份有限公司向港交所提交上市申请书。 来源：滚动播报 ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Zhejiang Jingxin Pharmaceutical Co., Ltd. 浙江京新藥業股份有限公司 (a joint stock company incorporated in the People's Republic ...

警告 本公告乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會 （「證監會」）的要求而刊發，僅用作向香港公眾人士提供資料。 閣下閱覽本公告，即表示閣下知悉、接納並向浙 江 京 新 藥 業 股 份 有 限 公 司（「 本 公 司 」）、 其 獨 家 保 薦 人 、 獨 家 整 體 協 調 人 、 顧 問 或 包 銷 銀 團 成 員 表 示 同 意 ： 香 港 聯 合 交 易 所 有 限 公 司 及 證 券 及 期 貨 事 務 監 察 委 員 會 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Zhejiang Jingxin Pharmaceutical Co., Ltd. 浙 江 京 新 藥 業 股 份 有 限 公 司 （ 於中華人民共和國註冊成立的股份有限公司 ） 於本公司招股章程根據香港法例第32章公司（ 清盤及雜項條文 ）條例送呈香港公司 註冊處處長註冊之前，不會向香港公眾人士提出要約或邀請。倘於適當時候向香 港公眾人士提出要約或邀請，有意投資者務請僅依據本 ...

（文章来源：证券日报） 证券日报网讯 2月8日，京新药业在互动平台回答投资者提问时表示，公司的降脂新药PL（a）JX2201的 临床I期接近尾声。 ...

证券日报网讯2月8日，京新药业（002020）在互动平台回答投资者提问时表示，公司的降脂新药 PL(a)JX2201的临床I期接近尾声。 ...

Core Insights - The Chinese generic drug industry is undergoing significant changes due to policy factors, including the implementation of the drug marketing authorization holder system and early resolution mechanisms for patent disputes, which are reshaping the competitive landscape [1][11]. Industry Overview - The number of generic drug products that have passed or are deemed to have passed evaluations in China reached 2,998 in 2024, an increase of 1,008 from 2023, representing a year-on-year growth of 50.65% [1][11]. - The proportion of contract manufacturing among these evaluated generic drug products reached 33% in 2024, up from 12% in 2020, indicating a trend towards deeper industry collaboration and resource allocation [1][11]. Generic Drug Consistency Evaluation - The consistency evaluation of generic drugs ensures that they meet the same quality and efficacy standards as original drugs, which is crucial for patient safety and effective treatment [2][3]. - The evaluation process includes determining reference formulations, conducting pharmaceutical research, and ongoing monitoring to ensure compliance with quality and safety standards [2][3]. Industry Policies - Recent policies have been introduced to enhance the quality of generic drugs and promote their market acceptance, including the 2025 guidelines for deepening drug regulation reforms [5][6]. - The establishment of a reference formulation directory is essential for conducting consistency evaluations, with 87 batches published by the National Medical Products Administration by the end of 2024 [9]. Market Dynamics - The market for chemical generic drugs in China is projected to be 868.3 billion yuan in 2024, showing a decline of 3% year-on-year, with the market share of chemical generics in the overall drug market decreasing from 60% in 2018 to 50% in 2024 [7][8]. - The competitive landscape is becoming increasingly polarized, with leading pharmaceutical companies gaining significant market share while smaller firms face challenges due to funding and research limitations [11]. Key Companies - Notable companies in the generic drug consistency evaluation sector include Tigermed Pharmaceutical Technology Co., Ltd., Huahai Pharmaceutical Co., Ltd., and Hengrui Medicine Co., Ltd., among others [1][11]. - Tigermed reported a revenue of 1.71 billion yuan in clinical trial services for the first half of 2025, reflecting a 3.07% increase year-on-year, while Hengrui Medicine achieved a revenue of 13.693 billion yuan, up 12.85% [12][14]. Future Trends - The focus of generic drug evaluations is expected to shift towards high-tech barrier products, such as controlled-release formulations and complex injectables, requiring enhanced reverse engineering and pharmaceutical research capabilities [15][16]. - The production model is transitioning from batch production to continuous manufacturing, which aims to ensure consistent quality and compliance with evaluation standards [15][16]. - Companies are encouraged to adopt a full lifecycle management approach for their products, emphasizing ongoing research and optimization post-evaluation to maintain market leadership [16].

证券代码：002020 证券简称：京新药业 公告编号：2026012 浙江京新药业股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 重要提示： 网络投票：通过深圳证券交易所交易系统进行网络投票的具体时间为 2026 年 1 月 28 日 9:15—9:25,9:30—11:30 和 13:00—15:00；通过深圳证券交易所 互联网投票系统进行网络投票的具体时间为 2026 年 1 月 28 日 9:15 至 15:00 的 任意时间。 2、现场会议地点：浙江省新昌县羽林街道新昌大道东路 800 号本公司行政 楼一楼会议室。 3、会议召开方式：本次会议采取现场投票与网络投票相结合的方式。本次 股东会通过深圳证券交易所交易系统和互联网投票系统向公司股东提供网络形 式的投票平台，股东可以在网络投票时间内通过上述系统行使表决权。 4、会议召集人：浙江京新药业股份有限公司董事会。 5、会议主持人：公司董事长吕钢先生。 6、本次会议的召集、召开与表决程序符合有关法律、法规、规章和公司章 1、本次股东会无否决提案的情况； 2、 ...

法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于浙江京新药业股份有限公司 2026 年第一次临时股东会的 上海市锦天城律师事务所 关于浙江京新药业股份有限公司 2026 年第一次临时股东会的 法律意见书 致：浙江京新药业股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受浙江京新药业股份有限公 司（以下简称"公司"或"京新药业"）委托，就公司召开 2026 年第一次临时股东 会（以下简称"本次股东会"）的有关事宜，根据《中华人民共和国公司法》（以 下简称《公司法》）、《上市公司股东会规则》等法律、法规、规章和其他规范性 文件以及《浙江京新药业股份有限公司章程》（以下简称《公司章程》）的有关规 定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚 ...